Seattle Genetics announces FDA approval of ADCETRIS® (Brentuximab Vedotin) with chemo
Seattle Genetics announced a new approval for ADCETRIS® (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the FDA for adults with previously untreated sALCL or other CD30-expressing PTCL. November 16, 2018